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Introduction

In recent years, patenting biological functions has become the central
topic of the debate over biotech patent policy. Courts have faced
increasingly difficult questions such as research tool patents,1 and so called
"reach-through" claims. 2 The concern over patenting biological functions
reached its high-water mark when the Supreme Court granted certiorari in
Labcorp v. Metabolite,3 where the disputed patent claimed a correlation
between an elevated level of homocysteine and a deficiency in B vitamins
in humans.4
In Labcorp, the patent at issue involved methods for diagnosing
vitamin B12 or folic acid deficiency.5 Simply put, it involved a biological
function in the human body: when vitamin B 12 or folic acid is deficient, a
chemical called homocysteine cannot be properly metabolized; thus, the
level of homocysteine increases in our body.6 Knowing this functional
correlation, scientists can directly assay homocysteine to screen for vitamin
B12 or folic acid deficiency.7 Metabolite, the licensee of the patent,
sublicensed the patent to Labcorp. 8 When an alternative method of
homocysteine assay became available on the market, Labcorp switched to

1. The National Institutes of Health ("NIH") defines research tools as "tools that scientists
use in the laboratory, including cell lines, monoclonal antibodies, reagents, animal models,
growth factors, combinatorial chemistry and DNA libraries, clones, and cloning tools (such as
PCR), methods, laboratory equipment and machines." Principles and Guidelines for Recipients
of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research
Resource: Final Notice, 64 Fed. Reg. 72,090, 72,092 n.1 (Dec. 23, 1999).
2. "'Reach-through claim' . . . means a claim to a future invention based on a currently
disclosed invention." Stephen G. Kunin, Mark Nagumo, Brian Stanton, Linda S. Therkom &
Stephen Walsh, Reach-Through Claims in the Age of Biotechnology, 51 AM. U. L. REv. 609, 618
n.59 (2002).
3. Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006).
4. Id. at 2924 (the claim in dispute reciting a method for detecting a deficiency of
cobalamin or folate in warm-blooded animals comprising the steps of: assaying a body fluid for
an elevated level of total homocysteine; and correlating an elevated level of total homocysteine in
said body fluid with a deficiency of cobalamin or folate).
5. Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1358 (Fed. Cir.
2004).
6. Id.
7. Id.
8. Id. at 1359.
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the alternative assay and discontinued royalty payments to Metabolite. 9
Thereafter, Metabolite sued Labcorp, alleging that the use of the alternative
assay infringed its patent.' ° The Federal Circuit held that the patent was
valid and that Labcorp willfully infringed the patent." Labcorp filed a
petition for certiorari to the Supreme Court, contending that the patent
claim was invalid as unpatentable subject matter.
After hearing oral
arguments, the Supreme Court dismissed the writ of certiorari as
improvidently granted because the issue presented was not raised in the
decision below. 3
Although the fundamental purpose of patent law is to promote
progress,' 4 some judges and scholars worry that "too much patent
protection can impede rather than 'promote the Progress of Science and
useful Arts,' the constitutional objective of patent and copyright
protection."' 5 This seems particularly a concern when it comes to claiming
biological functionality. In biological and chemical arts, inventors have no
difficulty in finding functional characteristics that cover a broad scope. For
example, a drug functions in human cells by inhibiting specific protein
targets,' 6 an antibody works by recognizing and binding to a specific
region of the antigen,' 7 a polynucleotide probe detects a target generic
material by hybridizing to a specific region of a genomic DNA. 8
The impact of claiming biological functionality is enormous. Many
research tool and "reach-through" patents are the results of functional
claiming. Due to their broad scope, the research tool patents potentially
can cover prior art compounds. Even more significantly, the "reachthrough" claims cast shadows on future development and downstream
innovations involving the claimed biological functionality. On the other
hand, an argument in favor of allowing functional claims is, "incentives
may matter" to promote the upstream9 discoveries because they "may prove
''
of great benefit to the human race.

9.

Id.

10. Id.
11. Id. at 1358.
12. Lab. Corp. ofAm. Holdings, 126 S. Ct. at 2925.
13. Id.at2921.
14. U.S. CONST. art. 1, § 8, cl. 8.
15. Lab Corp. of Am. Holdings, 126 S. Ct. at 2922 (Breyer, J., dissenting); see also,
Rebecca S. Eisenberg & Michael A. Heller, Can Patents Deter Innovation? The Anticommons in
BiomedicalResearch, 280 SCIENCE 698 (1998).
16. See, e.g., Univ. of Rochester v. G.D. Searle & Co., 358 F.3d 916 (Fed. Cir. 2004).
17. See, e.g., Chiron Corp. v. Genentech, Inc., 363 F.3d 1247 (Fed. Cir. 2004).
18. See, e.g., Enzo Biochem, Inc. v. Gen-Probe Inc., 296 F.3d 1316 (Fed. Cir. 2002).
19. Lab Corp. ofAm. Holdings, 126 S. Ct. at 2922 (Breyer, J., dissenting).
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Courts and scholars have made various proposals to regulate the
research tool patents.2 ° Justice Breyer, in his dissenting opinion in the
Court's dismissal of Labcorp, made it clear that he would have invalidated
the Metabolite patent on the ground of unpatentable subject matter. 2'
Justice Breyer, however, recognized that "[t]he line between a patentable
'process' and an unpatentable 'principle' is not always clear. ''22 After all,
many patentable inventions rest upon the knowledge of natural phenomena,
and many process patents seek to make abstract intellectual concepts
workably concrete. 23 In addition, the "complex relationship [between
patents and innovation] is industry-specific at each stage of the patent
process. ' 24 Thus, for those cases at the boundary, the courts might be
reluctant to consider how broad or narrow the "natural phenomenon"
doctrine should be interpreted.
This Note argues that, where the patentable subject matter doctrine is
not easily applicable, the written description doctrine can provide a solution
to the issue of research tools. It is not necessary to draw an arbitrary line
between patentable subject matter and unpatentable scientific principle.
Part II of the Note explores the science and patenting of biological
pathways as an example of the problem presented by novel technologies to
the patent system. Part III of this Note examines the development of the
written description doctrine in the biotechnology patent cases. Part IV of
this Note proposes a new standard for functional claiming, and it illustrates
how the written description requirement applies to conform the scope of the
claims to the quid pro quo balancing of the patent system.

20. See, e.g., Rochelle Dreyfuss, Biotechnology Patents Get Special Treatment: Protecting
the PublicDomain of Science: Has the Timefor an Experimental Use Defense Arrived?, 46 ARIZ.
L. REV. 457 (2004); David C. Hoffman, A Modest Proposal: Toward Improved Access to
Biotechnology Research Tools by Implementing a Broad Experimental Use Exception, 89
CORNELL L. REV. 993 (2004); Marlan D. Walker, The Patent Research Tool Problem After
Merck v. Integra, 14 TEX. INTELL. PROP. L. J. 1 (2005).
21. Lab. Corp. of Am. Holdings, 126 S. Ct. at 2927 (Breyer, J., dissenting) ("[Cllaim 13 is
invalid no matter how narrowly one reasonably interprets [the patentable subject matter]
doctrine.").
22. Id. at 2926 (citing Parker v. Flook, 437 U.S. 584, 585 (1978)).
23. Id.at2926.
24. Id. at 2927 (citing Dan L. Burk & Mark A. Lemley, Policy Levers in Patent Law, 89
VA. L. REv. 1575, 1589 (2003)).
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II. Patenting Biological Pathways
A.

Biological Pathways in General and the NF-Kp 2 5 Pathway

A biological pathway is a group of cellular constituents wherein each
constituent is under the influence of one or more other cellular constituents
in the group. In the cell, there are many different kinds of enzymes that
catalyze a variety of different reactions. The biological pathway refers to a
specific sequence of events in which these reactions are carried out. For
example, a reactant is converted to a product by an enzyme. In turn, the
product of this enzyme becomes the reactant of a second enzyme in the
biological pathway. Like a cascade, the sequence of reactions continues on
until the final product is made through the series of steps in the pathway.
The NF-KP3 pathway is one of such pathways in the human body.
Like any biological pathway, the NF-xi3 pathway is a complicated
network for a number of reasons. First, NF-Kp3 is not a single protein, but a
family of closely related proteins that binds to a specific site of our
genome. 26 Second, NF-Ki3 regulates numerous genes in our immune
system,27 and consequently is implicated in many diseases.28 On the other
hand, in the cascade of the NF-Kp pathway, NF-K03 proteins themselves are
tightly controlled by several regulatory proteins. 29 Lastly, within the
general NF-Kic pathway, there are multiple sub-pathways wherein NF-Ki3
proteins can be activated via different activation mechanisms. 30 These sub-

25. NF-K03 stands for nuclear factor-13 protein. For a general review of NF-P13 pathway, see
Paul N. Moynagh, The NF-fi Pathway, 118 J. CELL SCl., 4589 (2005).
26. See Yixue Cao, Michael Karin, Florian R. Greten & Zhi-Wei Li, NF-KB in Cancer:
From Innocent Bystander to Major Culprit, 2 NAT. REV. CANCER 301, 303 (2002) ("There are

five mammalian reticuloendotheliosis family (REL)/nuclear factor of KcB (NF-B) proteins that
belong to two groups: those that do no do require proteolytic processing and those that do require
proteolytic processing.").
27. See Bharat B. Aggarwal, Aladin M. Boriek, Ashok Kumar & Yasunari Takada, Nuclear
Factor-f/: Its Role in Health and Disease, 82 J. MOL. MED. 434, 434 (2003) ("Nuclear factor-K[3
(NF-Kcj3) transcription factors are a family of structurally related eukaryotic transcription factors

that promote the expression of well over 150 genes involved in a variety of cellular processes.").
28. See id. ("The dysregulation of NF-Ki03 is associated with many disease states such as
AIDS, atherosclerosis, asthma, arthritis, cancer, diabetes, inflammatory bowel, disease, muscular

dystrophy, stroke, and viral infections. Recent evidence also suggests that the dysfunction of NFK013
is a major mediator of some human genetic disorders.").
29.

See Hideaki Kamata, Michael Karin & Jun-Li Luo, IKKI NF-KB Signaling: Balancing

Life and Death-A New Approach to Cancer Therapy, 115 J. CLIN.
("Many

stimuli activate NF-KB, mostly through

IK3

INVEST.

kinase-dependent

2625, 2625 (2005)
(IKK-dependent)

phosphorylation and subsequent degradation of IKO3
proteins. The liberated NF-B dimmers enter
the nucleus, where they regulate transcription of diverse genes encoding cytokines, growth
factors, cell adhesion molecules, and pro- and antiapoptotic proteins.").
30. See id. (There are at least two known NF-Kip activation pathways, the classical pathway
and the alternative pathway. The classical pathway is normally triggered in response to microbial
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pathways involve different cellular constituents, and regulate different
downstream genes. 31In sum, "NF-c[3] acts at the crossroads of many
signaling pathways."
Such biological pathways are perfect candidates for functional
claiming. Usually a patent may be granted if the patentee discovered a
compound(s) or a class of the compounds that are effective in treating a
certain disease. When the compound for treating a disease is not known,
the disclosure will not meet the written description requirement, unless it
relies on functional descriptions.3 2 There is little difficulty in finding such
functional descriptions in a biological pathway.
By describing the
regulatory proteins that control NF-ico3, one can characterize the activity of
NF-Ko3 proteins because they are tightly controlled by those regulatory
proteins. In turn, by describing the NF-K3 proteins, one can characterize
the activity of genes and proteins of the immune systems controlled by NF13. The potential functional claiming does not stop here. By simply
describing the NF-Kp3 proteins, one can essentially characterize the method
of treating any disease related to the NF-K[3 pathway.

B.

The NF-Kp Patent

The patentability of biological functionality remains unsolved after
Labcorp. The core issue continues to be a major concern to the
biotechnology and pharmaceutical industry, and continues to be the subject
of patent litigation.
On June 25, 2002, the United States Patent and Trademark Office
granted a patent on the NF-Kp pathway, 33 which claims various methods of
treating human disease by regulating the NF-Kp3 activity, based on the
functionality of the NF-Kf3 pathway.34
On the same day, Ariad
Pharmaceuticals, Inc., the exclusive licensee, filed a suit against Eli Lilly &
Company, "alleging that Lilly's sales and marketing of Evista and Xigris
and viral infection or exposure to proinflammatory cytokines. The alternative pathway is
triggered by certain members of the TNF cytokine family); see also, Michael Karin, Nuclear
factor-KB in Cancer Development and Progression,44 NATURE 431, 432 (2006) (describing a
third pathway "that can lead to NF-rB activation is independent of IKK and, instead, is based on
activation of casein kinase 2 (CK2) ... ").
31. Moynagh, supra note 25, at 4591.
32. See, e.g., Enzo Biochem, Inc. v. Gen-Probe Inc., 296 F.3d 1316 (Fed. Cir. 2002); Univ.
of Rochester, 358 F.3d 916; Regents of Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559 (Fed. Cir.
1997).
33. U.S. Patent No. 6,410,516 (filed June 5, 1995) [hereinafter "516 patent"]. The 516
patent was granted to inventors at the Massachusetts Institute of Technology, the Whitehead
Institute for Biomedical Research, and Harvard University. Ariad is the exclusive licensee of the
516 patent.
34. Ariad Pharms., Inc. v. Eli Lilly & Co., 2003 U.S. Dist. LEXIS 8030, at *3 (D. Mass.
May 12, 2003).
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constitute infringement of 20 claims of the '516 patent."3
The jury
36
awarded $65 million damages to Ariad.
With 203 claims, the 516 patent covers methods of reducing the
naturally occurring NF-K13 activity in cells affecting gene expression, for
example:
Claim 1. A method of inhibiting expression, in a eukaryotic cell, of a
gene whose transcription is regulated by NF-KcI, the method comprising
reducing NF-KI3 activity in the cell such that the expression of said gene is
inhibited.
Claim 203. A method of inhibiting expression, in a mammalian cell,
of a gene whose transcriptional activity is activated by binding of NF-KJ3 to
said gene, comprising introducing a nucleic acid decoy molecule into the
cell in an amount sufficient to inhibit expression of the gene, which decoy
includes a NF-K3 binding site that binds NF-Ko .37
Since the NF-K3 pathway controls "the expression of well over 150
genes involved in a variety of cellular processes, 38 the broad patent claims
could cover a wide range of drugs for treating various disease.3 9 In fact, the
patented method covers compounds known and patented before the
discovery of the NF-K13 pathway. Eli Lilly's osteoporosis and severe sepsis
drugs Evista and Xigris, both patented before Ariad's patent, were alleged
to infringe on Ariad's patent because "these drugs treat [diseases] by
inhibiting NF-[Ki3] activity" at the molecular level. 40 Allowing such
biological pathway patents could potentially remove even known materials
from the public domain.41
Relying on functional description, functional claiming of the
biological pathway could be classified into three categories. Under the first
scenario, a general method of modulating the pathway for treating diseases
is broadly claimed without claiming or disclosing any drug. An example of
this type of claim is claim 1 of Ariad's patent (supra). The second scenario
involves a method of modulating the pathway by introducing a class of
drugs, without disclosing any embodiment of the class. Claim 203 of
Ariad's patent (supra)is a good example of this type of claim, wherein a
35. Id.at *4.
36. Aaron Smith, Ariad v. Lilly, Part IT The Next Big Patent Battle, Aug. 4, 2006,
http://money.cnn.com/2006/08/04/news/companies/ariad/index.htm.
37. 516 patent, claims I and 203.
38. Aggarwal, Boriek, Kumar & Takada, supra note 27, at 434.
39. Ariad Pharms., Inc., 2003 U.S. Dist. LEXIS 8030, at *3 ( explaining that NF-K13
proteins "are associated with many diseases, including cancer, AIDS, sepsis, and atherosclerosis.
Inhibiting [the NF-K13] process has enormous and wide-ranging therapeutic effects.").
40. Id.at *34.
41. Ariad Pharms., Inc. v. Eli Lilly & Co., 2002 U.S. Dist. Ct. Motions 11280, 14 (U.S.
Dist. Ct. Motions 2006) (explaining that even aspirin and red wine affect the activity of NF-c13).
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class of nucleic acid decoy is claimed without disclosing any specific drug.
In the third scenario, a method of modulating the pathway is disclosed and
claimed, as well as some specific embodiments that are useable for treating
diseases. As far as patenting the biological pathway is concerned, all three
categories of patent claims can constitute research tools.
Some scholars have suggested that realities will limit any tendency
that patentee may have to limit access to or charge exorbitant licensing fees
on its patented biological pathway methods.42 First, Ariad has to license
such methods broadly because it could not possibly support all of the
feasible related research on its own. 4 This ensures "a wide range of
nonrivalrous research . .. using the patented methods."" Second, clinical
application of these methods would be complicated and unpredictable due
to the "intricate network of NF-Kp] interactions. ' A5 This, in combination
with "the cost and uncertainty of biotech research and development" in
general, will diminish the value of the patent and "mitigate [its] potential
negative impacts. 46
These arguments have some merit, particularly in an individual case
like the NF-Kp pathway. We still have difficulty, however, when dealing
with this problem broadly, for example, where the clinical application is
not as unpredictable or where the involved proteins have become the active
drug targets.
On the other hand, one may argue that a biological pathway, as a
natural phenomenon, is not patentable subject matter.4 7 However, the
patentable subject matter doctrine poses a low bar to patentability. The
Federal Circuit has held that a process is a patentable subject matter if it
produces "a useful, concrete and tangible result." 8 A method of treating
diseases, or a method of inhibiting gene expression, passes muster under 35
U.S.C. 101. 4 9 The mere involvement in a biological pathway does not
render a specific drug or a method of using that drug unpatentable subject

42. David E. Adelman, A Fallacy of the Commons in Biotech Patent Policy, 20 BERKELEY
TECH. L.J. 985, 1024 (2005).
43. Id. at 1026.
44. Id.
45. Id.
46. Id.
47. Ariad Pharms., Inc., 2002 U.S. Dist. Ct. Motions 11280, 3 (explainin that "[e]ach of the
limitations of the asserted claims of the '516 patent encompass the natural autoregulatory process
and are thus invalid under 35 U.S.C. § 101.").
48. In re Alappat, 33 F.3d 1526, 1544 (Fed. Cir. 1994).
49. Section 101 of the Patent Act provides that "[w]hoever invents or discovers any new
and useful process, machine, manufacture, or composition of matter, or any new and useful

improvement thereof, may obtain a patent therefore, subject to the conditions and requirements of
this title." 35 U.S.C. § 101 (2008).
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matter per se. In fact, all drugs modulate some biological pathways in
order to function in the human body. Thus, the courts would be hardpressed to announce the across-the-board unpatentability of such methods,
particularly where specific compounds have been disclosed.
The written description requirement, on the other hand, may be a more
appropriate means for assessing the patentability of biological pathway
patents because the written description limits the patent scope based on the
disclosure of the invention. To satisfy the written description requirement,
an invention involving a chemical genus requires a precise definition, such
as by structure, formula, or the chemical name of the claimed subject
matter sufficient to distinguish it from other materials, 50 or "functional
characteristics when coupled with a known or disclosed correlation
between function and structure." 51 Thus, the patenting of the biological
pathway can rely on functional characteristics coupled with correlation to
satisfy the written description requirement. However, as will be discussed
in Part III, the Federal Circuit has not developed a consistent body of law in
this area.

IIl. Development of Written Description Requirement in
Biotechnology Area
A.

Regents of Univ. of CaL v. Eli Lilly & Co- The Scope of the Claims
Limited to the Disclosed Embodiments of the Invention

Regents of Univ. of Cal. v. Eli Lilly & Co, limited the scope of the
claims to the disclosed embodiments of the invention. In Eli Lilly, the
inventors at University of California discovered the rat cDNA sequences
for PI and PPI insulin.5 2 However, the human, vertebrate and mammalian
cDNA were not discovered at the time of the application, and thus were not
disclosed. 53 In their application, the inventors broadly claimed not only the
cDNA sequences for rat insulin, but also the human, vertebrate and
mammalian PI and PPL. 54 The court invalidated those claims of the
undisclosed cDNA sequences, reasoning that "a generic statement" of
cDNA sequences "does not distinguish the claimed genus from others,

50. EliLilly& Co., 119 F.3dat 1568.
51. Enzo Biochem, Inc. v. Gen-Probe Inc., 296 F.3d 1316, 1324 (Fed. Cir. 2002).
52. Eli Lilly, 119 F.3d at 1562-1563. PI and PPI stand for preproinsulin and proinsulin,
respectively.
53. Id.at 1568.
54. Id.
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except by function.",55 Such generic statements, without more, are not
adequate written descriptions of the genus.56
The Lilly court thus adopted a rigorous written description
requirement standard, and rejected the patentability of broad functional
claiming. Under Lilly, a definition by function "does not suffice to define
the genus because it is only an indication of what the gene does, rather than
what it is." ' 57 "[T]he written description of an invention involving a
chemical genus . . . 'requires a precise definition, such as by structure,

formula, [or] chemical name,' of the
claimed subject matter sufficient to
58
distinguish it from other materials."
B.

Enzo Biochem, Inc. v. Gen-Probe Inc. - Functional Claiming May Satisfy

the Written Description Requirement
Enzo Biochem, Inc. v. Gen-Probe Inc., by contrast, allowed claims
having a broader scope than what was set out in the disclosed
embodiments.5 9 In Enzo, the patentee discovered three nucleic acid probes
and deposited them at the American Type Culture Collection, together with
six strains of Neisseria gonorrhoea and of Neisseria meningtidis. 60 The
patentee sought to claim the three deposited probes even though the
sequences of these probes were not determined.6' In addition, the patentee
claimed a genus of "nucleic acid probes thatselectively hybridize to the
genetic material of

.

.

. Neisseria gonorrhoeae" over that of Neisseria

meningitides. 62 The Federal Circuit, in its first decision, applied Lilly's test
and invalidated
the genus claim for failure to meet the written description
63
requirement.
A mere three months later, the Federal Circuit vacated its first
decision and held that "it is not correct ...

that all functional descriptions

55. Id.
56. Id.
57. Id.
58. Id.at 1562-1563.
59. Enzo Biochem, Inc. v. Gen-Probe Inc., 296 F.3d 1316 (Fed. Cir. 2002).
60. Id.at 1321.
61. Enzo Biochem, Inc. v. Gen-Probe Inc., 285 F.3d 1013, 1016 (Fed. Cir. 2002).
62. Enzo Biochem, Inc., 296 F.3d at 1320; see also, Wenrong Huang, Enzo's Written
Description Requirement: Can It an Effective Check Against Overly Broad Biotechnology
Claims?, 16 ALB. L.J. SC1. & TECH. 1, 17 (2006) (explaining that the genus comprises numerous
possible probes. "[E]ntirely different DNA sequences [can] display similar selectivity, but...
bind to other parts of the N. gonorrhoeae DNA... [i]t's like a blind person discovering the tail of
an elephant.").
63. Enzo Biochem, Inc., 285 F.3d at 1015 (The first Enzo court further invalidated the
claims to three deposited probes because a publicly accessible depository does not provide "such
descriptive means ...
that fully set forth the claimed invention.").
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of genetic material fail to meet the written description requirement., 64 The
Enzo II court held that even if the patentee did not disclose any structural
features commonly possessed by members of the genus, the application
could satisfy the written description requirement "if one of skill in the art
would find the generically claimed sequences described on the basis of
Enzo's disclosure of the hybridization function and an accessible structure.
.. ,65 Thus, under the Enzo I decision, "functional characteristics when
coupled with a known or disclosed correlation between function and
structure, or some combination66of such characteristics," may satisfy the
written description requirement.
The Enzo II decision has been criticized for "relax[ing] the
requirement of Eli Lilly and open[ing] a door for overly broad claims. 67
However, a distinction can be made between Enzo and Eli Lilly. In Enzo,
"the claimed nucleotide sequences preferentially bind to the genomic DNA
of the deposited strains of [Neisseria] gonorrhoeae and have a
complementary structural relationship with that DNA ... .,,68 By contrast,
this "complementary structural relationship" is absent in Eli Lilly. There,
the patentee defined the claimed cDNA sequences by "the mere name
'cDNA"' or "the name of the protein., 69 Thus, one can distinguish Enzo
from Eli Lilly by examining the presence or absence of a correlation
between the function and structure.
C.

The "Full Characterization" Requirement

Subsequent to Enzo H, the Federal Circuit has developed further
requirements for functional claiming, and held that applicants cannot
"define the unknown [structures] by . . . another unknown," when relying

on the functional characteristics coupled with a known or disclosed
correlation between function and structure.7 ° In Noelle v. Lederman, the
applicant discovered a "mouse" form of a monoclonal antibody that
specifically binds to a CD40CR antigen. 71 As the patentees in Eli Lilly, the

64. Enzo Biochem, Inc., 296 F.3d at 1324.
65. Id. at 1328.
66. Id. at 1324.
67. Huang, supra note 62, at 13. (2006); see also, Paula K. Davis, Questioning the
Requirement for Written Description: Enzo Biochem v. Gen-Probe and Overly Broad Patent
Cases, 37 IND. L. REV. 467, 490-491 (2004) ("The [Enzo's genus] claims are not limited to
specific metes and bounds but instead describe an unknown but potentially astronomical number
of compounds of unknown sequences and structures, yielding overly broad claims.").
68. Enzo Biochem, Inc., 296 F.3d at 1328.
69. Regents of Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559, 1569 (Fed. Cir. 1997).
70. Noelle v. Lederman, 355 F.3d 1343, 1349 (Fed. Cir. 2004).
71. Id at 1345-1346; Antibody is a Y-shaped protein on the surface of B cells that is
secreted into the blood or lymph in response to an antigenic stimulus, such as a bacterium, virus,
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applicant sought to claim more than the scope of the disclosure-the
"human" form of the antibodies and the "genus" form of the antibodies.72
As in Eli Lilly, the Federal Circuit held that the applicant "failed to disclose
the structural elements of human CD40CR antibody or antigen ...

,"

and

thus did not provide a sufficient written description of the claimed "genus"
or "human" form of antibodies.7 3 However, unlike in Eli Lilly, the Federal
Circuit held that it would have allowed functional claiming if the applicants
had disclosed a "fully characterized antigen. 7 4 Here, the binding affinity
to the antigens alone could not sufficiently describe the "human" form of
antibody. Therefore, "[i]f Noelle had sufficiently described the human
by simply
form of CD40CR antigen, he could have claimed his antibody
75
stating its binding affinity for the'fully characterized' antigen."
The Federal Circuit further articulated the "full characterization"
requirement in In re Wallach: if the functional "characterization contributes
little ...

to the description" of the claimed genus, the written description

76
requirement is not met, even if there is "disclosure of a partial structure."
There, the applicants sought to claim a genus of genes encoding for a
protein, even though 95 percent of the amino acid sequence was not
determined at the time of the application.7 7 The Federal Circuit rejected the
applicants' argument that the written description was satisfied because they
"were in possession of the protein" and the sequences of the protein were
merely "an inherent property of the protein. 78 Physical possession does
not amount to knowledge of the sequence.79
Following Enzo II, the Wallach court did not reject patentability by
functional claiming, but held that "functional description can be sufficient
only if there is also a structure-function relationship known to those of
parasite, or transplanted organ, and that neutralizes the antigen by binding specifically to it; an
immunoglobulin; see Noelle, 355 F.3d at 1346 (the applicants claimed the "mouse" form of
CD40CR antibody in claim 42 of the application: "A monoclonal antibody or fragment thereof
which specifically binds to an antigen expressed on activated T cells, wherein said antigen is
specifically bound by the monoclonal antibody secreted by hybridoma MR1 which hybridoma
has been deposited and accorded ATCC Accession No. HB 11048.").
72. Id. at 1346 (explaining that the "human" form of CD40CR antibody was claimed in
claim 52: "The monoclonal antibody or fragment of Claim 51, wherein said CD40CR is
expressed by activated human T cells." The "genus" form of CD40CR antibody was claimed in
claim 51: "A monoclonal antibody or fragment thereof which specifically binds CD40CR.").
73. Id. at 1349.
74. Id.
75. Id.
76. In re Wallach, 378 F.3d 1330, 1334 (Fed. Cir. 2004) (stating that the applicants
disclosed a partial (5 percent) amino acid sequence of a protein together with the molecular
weight of the complete protein).
77. Id. at 1332.
78. Id. at 1334.
79. Id. at 1334-1335.
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ordinary skill in the art.",80 Disclosure of a complete amino acid sequence
may suffice for written description of the genus of the DNA molecules
encoding for the protein because, analogous to the case of the nucleotide
hybridization in Enzo, "such a well-known relationship exists between a
nucleic acid molecule's structure and its function in encoding a particular
amino acid sequence
.,,8
However, a mere partial sequence cannot
describe the structures of the genus.8 2 There is no evidence of "any known
or disclosed correlation between the combination of a partial structure of a
protein, the protein's biological activity, and the protein's molecular
weight, ... and the structure of the DNA encoding the protein ....
,83
D. No-compound, No-patent - Univ. of Rochester v. G.D. Searle & Co.
In Univ. of Rochester v. G.D. Searle & Co., the Federal Circuit
seemed to have returned to Eli Lilly's holding, limiting the scope of the
claims to the disclosed embodiments of the invention. 84 InRochester, the
University discovered the existence and separate functions of two distinct
cyclooxygenases, "COX-l" and "COX-2. 85 The University "hypothesized
that it would be possible to reduce inflammation without gastrointestinal
side effects if a method could be foundfor selectively inhibiting the activity
of COX-2 . . . without inhibiting COX-1 activity." 86 The University
"developed a screening assay for use in determining whether a particular
drug displayed such selectivity," 87 but failed to disclose or identify even a
single selective compound.88 The claims to assay methods were allowed
and issued in a prior patent. 89 The University further sought to patent a
method of selectively inhibiting COX-2 activity in a human host by
administering a non-steroidal compound that selectively inhibits COX-2
activity to a human host in need of such treatment. 90 The Federal Circuit
ruled that this method claim was invalid for lack of written description,
because the application did not disclose any COX-2 selective compound.

80. Id. at 1335.
81. Id. (explaining that given the amino acid sequence, one can determine the chemical
structure of all nucleic acid molecules that can serve the function of encoding that sequence).

82. Id.
83. Id
84.
85.
86.

Univ. of Rochester v. G.D. Searle & Co., 358 F.3d 916 (Fed. Cir. 2004).
Id.at 917.
Id.at918.

87.
88.
89.
90.

Id.
Id at 928.
Id.
Id at918.
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"Without such disclosure, the claimed methods cannot be said to have been
described." 91
However, the Rochester court did not close the door for functional
claiming in pharmaceutical patents, and has left many questions
unanswered. In rejecting Rochester's written description requirement
arguments, the court seemed to suggest that functional claiming was not
available because the genus was described by a "vague functional
description. 9 2 An ordinarily skilled artisan would not be able to "identify
any compound based on this vague functional description as 'a nonsteroidal compound that selectively inhibits activity of the PGHS-2 gene
product."' Conversely, if the functional description was not vague, the
court would be willing to consider the functional claiming.

IV. Applying the Written Description Requirement Doctrine to
Patents on Biological Pathways
A.

Scholastic Responses to the Federal Circuit's Written Description
Jurisprudence in Biotechnology Inventions

Thus far, the Federal Circuit precedents regarding the written
description requirement have been confusing. In Eli Lilly, the court limited
the scope of the claims to disclosed embodiments of the invention. 93 The
Enzo II decision allowed claims having scope broader than what was set
out in the disclosure. 94 In Rochester, the court took a no-drug, no-patent
approach.95 These conflicting decisions have "foster[ed]
further confusion
96
in what is already a confusing area of our precedent."
Commentators have criticized the need for a separate written
description requirement. 97 Some commentators have advocated that an
91. Id. at 927.
92. Id. at 928.
93. Regents of Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559, 1559 (Fed. Cir. 1997).
94. Enzo Biochem, Inc. v. Gen-Probe Inc., 296 F.3d 1316 (Fed. Cir. 2002).
95. G.D. Searle & Co., 358 F.3d at 926.
96. Enzo Biochem, Inc. v. Gen-Probe Inc., 323 F.3d 956, 988 (Fed. Cir. 2002) (Linn, J.,
dissenting). See also, Guang Ming Whitley, A Patent Doctrine without Bounds: The "Extended"
Written Description Requirement, 71 U. CM. L. REV. 617, 629 (2004) ("The extended written
description requirement ... is confusing to the courts that must apply Federal Circuit law.").
97. See, e.g., Robin Feldman, The Inventor's Contribution, 2005 UCLA J.L. & Tech. 6
(2005) (critiquing the need for a separate written description requirement). See also, Stephen J.
Burdick, Moba v. Diamond Automation, Inc.: Questioning the Separate Written Description
Requirement, 19 Berkeley Tech. L.J. 133 (2004) (arguing that the effects of the separate written
description requirement is redundant with enablement and new matter requirements, and that the
separate written description requirement should be eliminated entirely); Dan L. Burk & Mark A.
Lemley, Biotechnology's Uncertainty Principle, 54 CASE W. RES. L. REV. 691 (2004); Mark D.
Janis, On Courts Herding Cats: Contending with the "Written Description" Requirement (And
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optimal biotechnology patent policy should require "a fairly low disclosure
requirement" coupled with "a fairly high obviousness threshold, and argued
that a variety of policy levers (such as utility and abstract ideas doctrines)
might be employed to prevent unnecessary upstream patents that threaten
to hold up downstream innovation. 98 The proposed policy, however, might
still result in overreaching upstream patents, particularly for inventions that
do meet utility and abstract ideas standards, such as patenting on biological
pathways.
Other commentators recognized that issues addressed in the separate
written description doctrine properly reside in the disclosure inquiry and
reflect legitimate concerns, but argued that a separate written description
doctrine is unnecessary. 99 In particular, it has been strongly argued that the
issues addressed in the separate written description doctrine can be
resolved by harmonizing disclosure with other doctrines of patent law and
by properly applying traditional disclosure doctrines.10 0 Under this
proposal, information that could have been known should be reachable only
if it does not require undue experimentation,' 0' and information that could
not have been known at the time of the application should be beyond the
reach of the invention.' 0 2 The same rationale and analysis, however, are
equally applicable to the separate written description requirement in
priority cases, 103 a requirement that has been firmly established for
decades.104 If courts were to adopt this approach, they will have to abandon
the separate written description requirement all together, whether in
priority cases or in original claims cases. Alternatively, if we are going to
keep the written description requirement, a better standard for meeting the
written description requirement is needed because of the above concerns.

Other Unruly Patent Disclosure Doctrines), 2 Wash. U. J.L. & Pol'y 55 (arguing that the
distinction between the written description and enablement requirements is artificial).
98. See, e.g., Burk & Lemley, supra note 97, at 737 (explaining that biotechnology is

properly described in part by the anti-commons theory and in part by prospect theory, and that a
rational patent policy should seek to minimize the anti-commons problems and give inventors
control to induce them to walk the uncertain path towards commercial development).
99.

See, e.g., Feldman, supra note 97, at 135. See also, Burdick, supra note 97.

100. Feldman, supra note 97, at 134.
101. Id.
102.

Id.; see also, Feldman, Rethinking Rights in Biospace, 79 S.Cal.L.Rev. 1 (2005).

103. Feldman, supra note 97, at 24. (noting that the written description inquiries in priority
cases and in original claims cases concern the same issue, and the difference between two
inquiries is just a matter of timing).
104. In cases involving priority issues, the U.S. Patent and Trademark Office and the court
have to determine which of two inventors could properly claim to be the first to invent. See, e.g.,
In re Baker, 559 F.2d 588 (C.C.P.A. 1977) (noting that a separate written description requirement
is "astatutory requirement duly recognized by the courts").
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Proposal: A New Standard for Meeting the Written Description
Requirement

1. A "Common Feature" Test

Recognizing the need for certainty for inventors, practitioners, and the
courts, this Note proposes a "common feature" test that resolves this issue,
replaces the "possession of the invention" test, 10 5 or "complementary
structural relationship" test, 10 6 and avoids many uncertainties under the
precedents.
Under the "common feature" test, there are two conditions for
describing a genus by functional characterization: (1) a "fully
characterized" defining material; 10 7 and (2) a defining correlation sufficient
to identify a "common feature" of the structures. Under this approach,
functional claiming would not meet the written description requirement in
two instances. First, a genus could not be defined by "another unknown
[material],' 0 8 nor could it be defined if the functional "characterization
contributes little ...

to the description" of the claimed genus. 10 9 Second,
0

the genus could not be defined by a mere "vague functional description."''
However, the "common feature" test would not completely preclude
the patentability of functional claiming. Under this approach, functional
claiming could meet the written description requirement in two scenarios,
provided that the defining material itself is fully characterized. First, the
defining correlation is of a "complementary structural relationship,""' or
"known to those of ordinary skill in the art.""11 2 Second, absent such a
complementary or well-known correlation, the written description
requirement would be met if the defining correlation would sufficiently
identify a common feature of the structures of the genus.
The inquiry under the common feature test would not focus on
whether or not any specific working examples were disclosed. Some
working examples would be helpful for establishing such a common
feature. However, even with no compound, the written description
requirement would be met if the defining correlation, coupled with ordinary

105. See, e.g., Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1564 (Fed. Cir. 1991) ("[T]he
applicant must ...
convey with reasonable clarity to those skilled in the art that, as of the filing
date sought, he or she was in possession of the invention.").
106. Enzo Biochem, Inc., 296 F.3d at 1328.
107. Noelle v. Lederman, 355 F.3d 1343, 1349 (Fed. Cir. 2004).
108. Id.
109. In re Wallach, 378 F.3d 1330, 1334 (Fed. Cir. 2004).
110. Univ. of Rochester v. GD. Searle & Co., 358 F.3d 916, 928 (Fed. Cir. 2004).
111. EnzoBiochem, Inc., 296 F.3d at 1328.
112. Wallach, 378 F.3d at 1335.
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skill in the art, would reveal a common feature of the genus. By taking this
approach, the test avoids a hard-and-fast no-compound, no-patent rule. The
next part of the Note uses three hypothetical claims to illustrate how this
test can be apply to functional claiming of biological pathways.
C. Three Scenarios of Functional Claiming On Biological Pathways
As discussed briefly in Part II. 2, supra, there could be three
categories of functional claiming of biological pathways. The first kind
would claim a general method of modulating the pathway without claiming
or disclosing any drug. The second would claim a method of modulating
the pathway using a genus of drugs, without specific examples of the
claimed genus. The third would claim a method of modulating pathways
using a genus of drugs, accompanied with some examples of specific drugs.
To summarize, these three categories of functional claiming can be
formulated as the following:
Hypothetical claim 1: A method of modulating X pathway by
reducing the activity of protein X in the cell.
Hypothetical claim 2: A method of modulating X pathway by
inhibiting protein X with a genus of inhibitors Y.
The specification does not disclose any working example of inhibitors
Y.
Hypothetical claim 3: A method of modulating X pathway by
inhibiting protein X with a genus of inhibitors Y.
The specification discloses some working examples of inhibitors Y.
The details of the disclosure and the scope of the claims correspond
well to the process of research and development in biotechnology
inventions. At the early stage, a pathway is discovered, important players
such as the key enzymes in the pathway are revealed, and the relationship
between this pathway and diseases is elucidated. As the research goes on,
researchers conceive that a certain class of compounds will potentially
inhibit the key enzyme and thus could constitute an effective treatment for
diseases.
Nonetheless, as is typical for the biotechnology and
pharmaceutical industry, no compound is possible prior to a timeconsuming and expensive process. If he or she is lucky, a researcher may
eventually discover some effective compounds.
Essentially, discoveries of pathways, at the early stage, are "upstream
discoveries that may be useful in a variety of different future research paths
or for the development of a variety of commercial products."'" 13 Does this

113. Arti K. Rai, Regulating Scientific Research: Intellectual Property Rights and the Norms
of Science, 94 Nw. U. L. REV. 77, 115 (1999).
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kind of discovery, being remote from any commercial development, merit
the award of a patent and exclusion rights?
D. Application of the Proposal to the Biological Pathway Patents
Hypothetical claim 2 closely resembles the selective inhibitor method
claimed in Rochester. In Rochester, the claim was directed to "[a] method
for selectively inhibiting [enzyme] activity [by] administering a nonsteroidal compound . . . ," without disclosing a single non-steroidal
compound.11 4 Essentially, the University claimed a method of inhibiting
the enzyme with a genus of non-steroidal compounds, without disclosing
any species. Here, as in Rochester, hypothetical claim 2 does not disclose
any specific compound. Thus, under Rochester's no-compound, no-patent
rule, a method of modulating X pathway by inhibiting protein X with a
genus of inhibitors Y would not meet the standard.
Hypothetical claim 1 claims an even broader scope than the selective
inhibitor method claimed in Rochester. By not claiming any genus of
compounds in its language, this type of claim in effect covers any genus of
compound that modulates the pathway. Thus, the method claim is
analogous to "a cure for cancer by utilizing a substance that attacks and
destroys cancer cells while leaving healthy cells alone."1 15 Such a claim is
"more theoretical than real," "such a 'cure' is illusory .
,1 6
Hypothetical claim 1 would not pass muster under Rochester either.
The fate of hypothetical claim 3 under current written description
precedents is uncertain. Unlike hypothetical claim 2, hypothetical claim 3
is supported by some working examples. Should the scope of the claims be
limited to the disclosed embodiments? If functional claiming is to be
allowed, would this disclosure of working examples overcome the "vague
functional description" rejection in Rochester?1t 7 The Rochester court left
little guidance in determining how many examples are necessary to render
the functional description not vague.
Under the "common feature" test, hypothetical claim 1 also fails to
satisfy the written description requirement because the defining correlation
does not identify the common feature of the structures. First, a biological
pathway often has multiple defining materials," 18 and each defining
material may define a different class of inhibitors. Second, a complex

114. U.S. Patent No. 5,837,479, claim 1,(filed June 7, 1995).
115. University of Rochester v. G.D. Searle & Co., 249 F. Supp. 2d 216, 228 (W.D.N.Y.
2003).
116. Id.
117. G.D. Searle & Co., 358 F.3d at 928.
118. See supra Part II. NF-ic3 is a family of five related proteins.
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biological pathway usually comprises multiple sub-pathways.1 1 9 The
correlation defined by each sub-pathway is dissimilar to the others,
resulting in a different class of inhibitors. Third, because the defining
material may be controlled by other cellular constituents, 120 the inhibition
of the defining material could be accomplished indirectly by regulating
those cellular constituents. The correlation defined by indirect inhibition
would differ significantly from the correlation defined by direct inhibition.
Due to these variables, it is unlikely that the defining correlation would be
of a "complementary structural relationship,"' 21 or "known to those of
ordinary skill in the art."' 122 Further, it is unlikely that there is any common
feature among the large variety of inhibitors defined by the multiple
correlations.
Hypothetical claim 2, by focusing on one genus of inhibitors,
eliminates many variables seen in hypothetical claim 1. There still might
be multiple defining materials. But claim 2 is unlikely to involve multiple
sub-pathways, and possibly involves only one inhibition mechanism, either
direct or indirect. 123 The "common feature" test would yield a different
result from that under the current precedents.
In most cases, the inhibition correlation does not identify a common
feature of the structures. The selective COX-2 inhibition method litigated
in Rochester, for example, comprises a variety of inhibitors that are
dissimilar to each other.' 24 Some selective COX-2 inhibitors are composed
of three six-member rings (Etoricoxib) or two six-member rings
(Nimesullde, Lumiracoxib), some others are composed of two six-member
rings plus one five-member ring (Celecoxib, Rofecoxib, Valdecoxib,
Deracoxib, Parecoxib). 125 Without some working examples in each of
these classes of inhibitors, an ordinary person skilled in the art has no way
to identity a common feature among all selective inhibitors.

119. See supra Part II. (There are multiple sub-pathways wherein NF-KP3 proteins can be
activated via different activation mechanisms).
120. See supra Part II. (NF-Ko3 proteins themselves are tightly controlled by several
regulatory proteins).
121. Enzo Biochem, Inc., 296 F.3d at 1328.
122. In re Wallach, 378 F.3d 1330, 1335 (Fed. Cir. 2004).
123. One of the most common means to inhibit an enzymatic activity is to block a binding
pocket or an "active site" of the enzyme-the region of an enzyme at which a chemical reaction
occurs, and to render it incapable of functioning in the cell. For example, HIV transcriptase
inhibitor and protease inhibitor function by binding to and inhibiting the active sites of HIV
transcriptase and protease.
124. Regina M. Botting, Timothy Hla, & Daniel L. Simmons, Cyclooxygenase Isozymes: The
Biology of ProstaglandinSynthesis and Inhibition, 56 PHARM. REV. 387, 407 (2004).
125. Id.
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In some cases, however, the inhibition correlation may identify a
common feature. For example, claim 203 of Ariad's patent claims a
method of inhibiting NF-ic3 protein by using a nucleic acid decoy
molecule. 26 Because NF-KO3 protein binds to a specific site of our
genome,1 27 a nucleic acid decoy inhibitor works by "directly targeting the
DNA-binding activity of individual NF-K[] proteins ....
,,128 The design
of the nucleic acid decoy imitates the sequences in the genome to which
NF-Kp3 protein binds, which contain a portion consensus among all binding
sequences.129 As a result, the designed decoy molecules are similar to each
other, all containing the consensus sequence.
Thus, the inhibition
correlation does identify a common feature of the decoy structures-the
consensus sequence of the binding sites. In this case, even without any
working example, a person ordinary skilled in the art could envision the
structure of the genus based on the common feature identified. The written
description requirement would be satisfied under the proposed test. This
approach avoids the arbitrary outcome resulting from the no-compound,
no-patent rule.
Under the "common feature" test, the fate of hypothetical claim 3 is
more predictable and certain. In cases like the selective COX-2 inhibition
method, working examples in each class of inhibitors are needed in order to
identity a common feature. In cases like the NF-cf3 decoy method, working
examples, though not needed, would certainly help the patentee's argument
in fulfilling her disclosure requirement. In other cases, the written
description requirement could be met if a sufficient number of working
examples would reveal a common feature. For example, there would be
pathways where the defining correlation does not itself identify a common
feature, in the absence of specific embodiments. With a number of
working examples, it becomes clear to an ordinary artisan that the
correlation necessarily requires all inhibitors to possess a common structure
motif. Then, under the "common feature" test, the written description
requirement should be satisfied.

126.
127.
128.

See supra Part II.
See Cao, Greten, Karin & Li, supra note 26, at 303.
See Qiutang Li & Inder M. Verma, NF-KB Regulation in the Immune System, 2 NAT.

REV. IMMUNOL. 725, 732 (2002).

129. See Marzia Bianchi, Rita Crinelli, Lucia Gentilini & Mauro Magnai, Design and
Characterizationof Decoy OligonucleotidesContainingLocked Nucleic Acids, 20 NUCLEIC ACID
RES. 2435 (2002).
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Application of the "Common Feature" Test to Existing Patentable
Inventions

Some may argue that, by adding a "common feature" requirement, this
new test would negatively affect the patentability of inventions that
currently would be patented. But the "common feature" test merely makes
the existing written description doctrine more workable in a muddy area of
the patent law. It would not affect the status of currently existing patents.
For example, "as long as an applicant has disclosed a 'fully
characterized antigen .... the applicant can then claim an antibody by its

binding affinity to that described antigen."' 130 The U.S. Patent and
Trademark Office routinely allows the antibody patents by functional
description of an antigen. Because an antigen may sometimes contain a
large number of epitopes, 13 1 the number of antibodies that can be made
from an antigen may correspondingly be a large figure.
The "common feature" test would produce a consistent result with the
current practice. Under this approach, the written description for even a
large number of antibodies would be satisfied if an ordinary person skilled
in the art could identify a "common feature," common structural motif, or a
substantial portion of the consensus structures among the genus. Because
antibody art is "well developed and mature," it is known that antibodies
only exist in five limited classes, all with "well-defined structural
characteristics .... .. 132 An ordinary artisan would readily recognize a
common structural motif among the spectrum of antibodies specific to an
antigen. Thus, the written description requirement is also met under the
"common feature" test. The new test would not affect the validity of the
existing patents, and is congruous with the previous court decisions in these
cases.
V. Conclusion
This Note proposes a new test to determine whether, and under which
circumstances, functional claiming may satisfy the written description
requirement. By excluding unwarranted functional claiming patents, the
proposed approach preserves the purpose of the written description
requirement: to "ensure that the scope of the [patent] does not overreach
the scope of the inventor's contribution to the field of art as described in

130. Noelle v. Lederman, 355 F.3d 1343, 1349 (Fed. Cir. 2004). The disclosure still needs to
satisfy other patentability requirements, such as enablement requirement, in order to be
patentable. Id.
131. An epitope is the localized region on the surface of an antigen that is capable of eliciting
an immune response and of combining with a specific antibody to counter that response.
132. Noelle, 355 F.3d at 1350 (quoting Enzo Biochem, Inc., 323 F.3d at 970).
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the patent specification."' 133 The "common feature" test would not deny
functional claiming in all cases. Rather, the proposed test would only
ensure that the scope 34
of the claims conforms to the quidpro quo balancing
of the patent system.
The proposed approach would provide a workable written description
doctrine, and reconcile the confusing, conflicting precedents on this
issue. 135 Apart from enhancing the certainty in conforming to the patent
law, this test would also avoid the drawing of an arbitrary "line between a
patentable 'process' and an unpatentable 'principle."",136 The approach
would provide sufficient incentive for pioneering inventions, preserve room
for the future, and thus promote progress and advance the purposes of
Patent law.

133. ADCO Products, Inc. v. Carlisle Syntec Inc., 110 F. Supp.2d 276, 290 (D. Del. 2000).
134. See, e.g., Enzo Biochem, Inc. v. Gen-Probe Inc., 296 F.3d 1316, 1330 (Fed. Cir. 2002)
("The public must receive meaningful disclosure in exchange for being excluded from practicing
the invention for a limited period of time.").
135. See supra Part III (discussing the development of written description requirement in
biotechnology area).
136. Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006).(Breyer,
J., dissenting) (citing Parker v. Flook, 437 U.S. 584, 585 (1978)).

